HOCPY:OTC-Hoya Corp (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 134.91

Change

-1.31 (-0.96)%

Market Cap

USD 46.93B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

HOYA Corporation, a med-tech company, provides high-tech and medical products worldwide. It operates through three segments: Life Care, Telecommunication, and Other. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics. It also operates Eyecity, a specialty retailer of contact lenses. In addition, the company provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; glass disks for hard disk drives; and imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. Further, it engages in the research, development, manufacture, and sale of photomasks for manufacturing flat panel displays. Additionally, the company offers ReadSpeaker, a speech synthesis software; and cloud services comprising Kinnosuke, a time and attendance management service, as well as Yonosuke, an electronic payslip service. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

+0.23 (+0.20%)

USD 106.82B
ESLOF EssilorLuxottica Société ano..

+5.46 (+2.42%)

USD 104.69B
HOCPF HOYA Corporation

N/A

USD 46.92B
CLPBF Coloplast A/S

-5.71 (-4.15%)

USD 31.46B
CLPBY Coloplast A

-0.05 (-0.36%)

USD 31.20B
TRUMF Terumo Corporation

-0.17 (-0.95%)

USD 29.47B
SAUHF Straumann Holding AG

+8.96 (+6.19%)

USD 23.15B
OCPNF Olympus Corporation

N/A

USD 20.54B
SRTOY Sartorius Stedim Biotech S.A

+0.24 (+1.15%)

USD 20.35B
SDMHF Sartorius Stedim Biotech S.A

+6.14 (+3.09%)

USD 20.03B

ETFs Containing HOCPY

1642:TSE 4.79 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.34% 66% D+ 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.34% 64% D 60% D-
Trailing 12 Months  
Capital Gain 26.30% 81% B- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.30% 74% C 74% C
Trailing 5 Years  
Capital Gain 65.11% 88% B+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.11% 82% B 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 9.38% 54% F 53% F
Dividend Return 9.38% 51% F 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.52% 76% C+ 76% C+
Risk Adjusted Return 34.07% 76% C+ 70% C-
Market Capitalization 46.93B 96% N/A 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector